Lemtrada and Common peroneal nerve dysfunction - a phase IV clinical study of FDA data

Summary:

Common peroneal nerve dysfunction is reported as a side effect among people who take Lemtrada (alemtuzumab), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Ampyra, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Common peroneal nerve dysfunction when taking Lemtrada. It is created by eHealthMe based on reports of 8,297 people who have side effects when taking Lemtrada from the FDA, and is updated regularly.

What is Lemtrada?

Lemtrada has active ingredients of alemtuzumab. eHealthMe is studying from 8,317 Lemtrada users. Check the latest studies of Lemtrada.

What is Common peroneal nerve dysfunction?

Common peroneal nerve dysfunction (dysfunction of nerve controlling movement and sensation to the lower leg, foot and toes) is found to be associated with 651 drugs and 1,130 conditions by eHealthMe. Check the latest studies of Common peroneal nerve dysfunction.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

8,297 people reported to have side effects when taking Lemtrada.
Among them, 30 people (0.36%) have Common peroneal nerve dysfunction.

Could Lemtrada cause Common peroneal nerve dysfunction?

Among these 30 people:

How long have people been on Lemtrada when they have Common peroneal nerve dysfunction? *

What is the gender of people who have Common peroneal nerve dysfunction when taking Lemtrada? *

female: 50 %
male: 50 %

What is the age of people who have Common peroneal nerve dysfunction when taking Lemtrada? *

What are other drugs people take besides Lemtrada? *

What are other side effects people have besides Common peroneal nerve dysfunction? *

Weakness: 20 people, 66.67%
Fatigue (feeling of tiredness): 18 people, 60.00%
Gait Disturbance: 15 people, 50.00%
Urinary Tract Infection: 15 people, 50.00%
Feeling Abnormal: 13 people, 43.33%
Dyspnea (difficult or laboured breathing): 12 people, 40.00%
Hypoaesthesia (reduced sense of touch or sensation): 12 people, 40.00%
Fall: 12 people, 40.00%
Insomnia (sleeplessness): 12 people, 40.00%
Chest Pain: 11 people, 36.67%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 22 people, 73.33%
Gait Disturbance: 4 people, 13.33%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 10.00%
Urinary Tract Infection: 2 people, 6.67%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 6.67%
Pulmonary Congestion (congestion in the lungs): 2 people, 6.67%
Insomnia (sleeplessness): 2 people, 6.67%
Weakness: 1 person, 3.33%
Cardiac Failure Congestive: 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Lemtrada and have Common peroneal nerve dysfunction?

- Check whether Common peroneal nerve dysfunction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lemtrada:

Lemtrada (8,317 reports)

Browse all side effects of Lemtrada:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Common peroneal nerve dysfunction:

Common peroneal nerve dysfunction (651 drugs)

Browse all the conditions that are associated with Common peroneal nerve dysfunction:

Common peroneal nerve dysfunction (1,130 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alemtuzumab (the active ingredients of Lemtrada) and Lemtrada (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.